Circulating proteomic biomarkers for cerebral amyloid angiopathy screening and risk stratification.

ABSTRACT:

Introduction

We systematically characterized plasma protein profiles in cerebral amyloid angiopathy (CAA) using proteomics and identified a hub protein panel for disease diagnosis and risk stratification.

Methods

A total of 146 patients with probable CAA and 128 community-dwelling controls were prospectively enrolled. Plasma samples underwent proteomic analysis, and the hub proteins were validated in two validation cohorts. Machine learning algorithms were applied to construct and validate the performance of the circulating panel.

Results

We identified 166 differentially expressed proteins in patients with CAA. Six hub proteins were selected to form the circulating panel, demonstrating excellent performance to distinguish patients from controls in all cohorts. Additio

SUBMITTER: Xu J 

PROVIDER: S-EPMC11881623 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature